tradingkey.logo

Trinity Biotech PLC

TRIB
0.800USD
+0.092+13.06%
Close 02/06, 16:00ETQuotes delayed by 15 min
15.41MMarket Cap
LossP/E TTM

Trinity Biotech PLC

0.800
+0.092+13.06%

More Details of Trinity Biotech PLC Company

Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.

Trinity Biotech PLC Info

Ticker SymbolTRIB
Company nameTrinity Biotech PLC
IPO dateOct 21, 1992
CEOGillard (John)
Number of employees- -
Security typeDepository Receipt
Fiscal year-endOct 21
AddressIda Business Park, Bray, Co Wicklow
CityDUBLIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIreland
Postal code18
Phone01135312955111
Websitehttps://www.trinitybiotech.com/
Ticker SymbolTRIB
IPO dateOct 21, 1992
CEOGillard (John)

Company Executives of Trinity Biotech PLC

Name
Name/Position
Position
Shareholding
Change
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Dr. James (Jim) Walsh, Ph.D.
Dr. James (Jim) Walsh, Ph.D.
Executive Director - Business Development
Executive Director - Business Development
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Mr. Tom Lindsay
Mr. Tom Lindsay
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Gary Keating, Ph.D.
Dr. Gary Keating, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Colm Molloy
Mr. Colm Molloy
Group Director of Human Resources and Culture
Group Director of Human Resources and Culture
--
--
Mr. Eric Ribner
Mr. Eric Ribner
Investors Relations
Investors Relations
--
--
Mr. Andrew Omidvar, Ph.D.
Mr. Andrew Omidvar, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Susan O'Connor
Ms. Susan O'Connor
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Dr. James (Jim) Walsh, Ph.D.
Dr. James (Jim) Walsh, Ph.D.
Executive Director - Business Development
Executive Director - Business Development
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Mr. Tom Lindsay
Mr. Tom Lindsay
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Gary Keating, Ph.D.
Dr. Gary Keating, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--

Revenue Breakdown

Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Clinical Laboratory
42.29M
74.41%
Point of care
9.09M
16.00%
Laboratory services
5.45M
9.59%
By RegionUSD
Name
Revenue
Proportion
Americas
44.98M
79.15%
Ireland
11.85M
20.85%
Eliminations
0.00
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Clinical Laboratory
42.29M
74.41%
Point of care
9.09M
16.00%
Laboratory services
5.45M
9.59%

Shareholding Stats

Updated: Sun, Feb 1
Updated: Sun, Feb 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
MiCo IVD Holdings, LLC
60.60%
Renaissance Technologies LLC
4.64%
Hunter Associates Investment Management LLC
2.85%
Citadel Advisors LLC
1.07%
Two Sigma Investments, LP
0.98%
Other
29.87%
Shareholders
Shareholders
Proportion
MiCo IVD Holdings, LLC
60.60%
Renaissance Technologies LLC
4.64%
Hunter Associates Investment Management LLC
2.85%
Citadel Advisors LLC
1.07%
Two Sigma Investments, LP
0.98%
Other
29.87%
Shareholder Types
Shareholders
Proportion
Corporation
60.60%
Hedge Fund
6.69%
Investment Advisor
5.47%
Research Firm
0.71%
Investment Advisor/Hedge Fund
0.46%
Other
26.08%

Institutional Shareholding

Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
52
2.76M
62.28%
+305.43K
2025Q3
51
972.36K
12.90%
+718.71K
2025Q2
50
3.17M
16.99%
-2.03M
2025Q1
53
3.13M
16.78%
-2.10M
2024Q4
50
4.89M
27.09%
-355.77K
2024Q3
47
4.97M
53.06%
-277.40K
2024Q2
45
4.94M
57.57%
-285.83K
2024Q1
44
5.20M
60.32%
-76.86K
2023Q4
40
3.94M
51.41%
+207.86K
2023Q3
42
3.97M
51.90%
+190.94K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
MiCo IVD Holdings, LLC
2.24M
60.6%
+1.79M
+400.00%
Dec 08, 2025
Renaissance Technologies LLC
171.36K
4.64%
+159.97K
+1404.10%
Sep 30, 2025
Hunter Associates Investment Management LLC
487.11K
13.19%
+399.53K
+456.18%
Sep 30, 2025
Citadel Advisors LLC
39.38K
1.07%
+39.38K
--
Sep 30, 2025
Two Sigma Investments, LP
36.23K
0.98%
+33.22K
+1101.76%
Sep 30, 2025
CAPTRUST Financial Advisors
27.25K
0.74%
+27.25K
--
Sep 30, 2025
Raymond James & Associates, Inc.
20.32K
0.55%
+15.25K
+300.77%
Sep 30, 2025
Williams & Novak Wealth Management, LLC
12.00K
0.32%
+7.60K
+172.73%
Sep 30, 2025
Becker Capital Management, Inc.
18.00K
0.49%
+14.40K
+400.00%
Sep 30, 2025
Geode Capital Management, L.L.C.
16.64K
0.45%
+13.31K
+400.06%
Sep 30, 2025
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Date
Ex-dividend Date
Type
Ratio
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
KeyAI